176 related articles for article (PubMed ID: 35143848)
21. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
North EJ; Newman JD
Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
[TBL] [Abstract][Full Text] [Related]
22. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence.
Natali A; Nesti L; Tricò D; Ferrannini E
Cardiovasc Diabetol; 2021 Sep; 20(1):196. PubMed ID: 34583699
[TBL] [Abstract][Full Text] [Related]
23. Metformin in patients with type 2 diabetes mellitus and heart failure: a review.
Kułaczkowska ZM; Wróbel M; Rokicka D; Gąsior M; Strojek K
Endokrynol Pol; 2021; 72(2):163-170. PubMed ID: 33970481
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
Sim R; Chong CW; Loganadan NK; Fong AYY; Navaravong L; Hussein Z; Khunti K; Lee SWH
Diabet Med; 2022 Mar; 39(3):e14780. PubMed ID: 34962662
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
Sharma A; Verma S
Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
[TBL] [Abstract][Full Text] [Related]
26. Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis.
Lavalle-Cobo A; Masson W; Lobo M; Masson G; Molinero G
High Blood Press Cardiovasc Prev; 2021 Nov; 28(6):605-612. PubMed ID: 34705249
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
[No Abstract] [Full Text] [Related]
28. Second revolution in cardiovascular prevention.
Chiang CE; Wang KL; Cheng HM; Sung SH; Chao TF
J Chin Med Assoc; 2020 Apr; 83(4):327-336. PubMed ID: 32101893
[TBL] [Abstract][Full Text] [Related]
29. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes.
Kalyani RR
N Engl J Med; 2021 Apr; 384(13):1248-1260. PubMed ID: 33789013
[No Abstract] [Full Text] [Related]
30. SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Shaughnessy AF
Am Fam Physician; 2021 Aug; 104(2):206. PubMed ID: 34383432
[No Abstract] [Full Text] [Related]
31. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
Thompson PL; Davis TME
Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
[TBL] [Abstract][Full Text] [Related]
32. Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
Neuen BL; Arnott C; Perkovic V; Figtree G; de Zeeuw D; Fulcher G; Jun M; Jardine MJ; Zoungas S; Pollock C; Mahaffey KW; Neal B; Heerspink HJL
Diabetes Obes Metab; 2021 Feb; 23(2):382-390. PubMed ID: 33043620
[TBL] [Abstract][Full Text] [Related]
33. Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis.
Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)
Lancet Diabetes Endocrinol; 2021 Dec; 9(12):825-836. PubMed ID: 34656210
[TBL] [Abstract][Full Text] [Related]
34. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
Verburg AFE; van den Donk M; Wiersma T
Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
[TBL] [Abstract][Full Text] [Related]
35. Metformin and cardiorenal outcomes in diabetes: A reappraisal.
Petrie JR; Rossing PR; Campbell IW
Diabetes Obes Metab; 2020 Jun; 22(6):904-915. PubMed ID: 32009286
[TBL] [Abstract][Full Text] [Related]
36. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
Packer M
Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
[No Abstract] [Full Text] [Related]
37. The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients.
Fadah K; Alashi A; Deoker A
Curr Cardiol Rep; 2022 Jan; 24(1):17-22. PubMed ID: 35000149
[TBL] [Abstract][Full Text] [Related]
38. The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.
Pan X; Xu S; Li J; Tong N
Front Endocrinol (Lausanne); 2020; 11():599355. PubMed ID: 33335511
[TBL] [Abstract][Full Text] [Related]
39. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.
Wright AK; Carr MJ; Kontopantelis E; Leelarathna L; Thabit H; Emsley R; Buchan I; Mamas MA; van Staa TP; Sattar N; Ashcroft DM; Rutter MK
Diabetes Care; 2022 Apr; 45(4):909-918. PubMed ID: 35100355
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.
Bonaventura A; Carbone S; Dixon DL; Abbate A; Montecucco F
J Intern Med; 2019 Jul; 286(1):16-31. PubMed ID: 30888088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]